In September 2011, the Korean Society of Hematology Lymphoma Working Party held a nationwide conference to establish a
consensus for assessing bone marrow (BM) involvement in patients with lymphoma. At this conference, many clinicians, hematopathologists, and diagnostic hematologists discussed various topics for a uniform
consensus in the evaluation process to determine whether the BM is involved. Now that the discussion has matured sufficiently to be published, we herein describe the
consensus reached and limitations in current methods for assessing BM involvement in patients with lymphoma.